Amicus Therapeutics Inc (FOLD)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Amicus Therapeutics Inc chart...

About the Company

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g

CEO

John Crowley

Exchange

NASDAQ

Website

http://www.amicusrx.com/

$16M

Total Revenue

886

Employees

$3B

Market Capitalization

-9.57

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $FOLD News

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

16d ago, source: Yahoo Finance

Last week saw the newest full-year earnings release from Amicus Therapeutics, Inc. (NASDAQ:FOLD), an important milestone in ...

Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates

18d ago, source: Yahoo Finance

Amicus Therapeutics, Inc. FOLD reported fourth-quarter 2023 adjusted earnings of 1 cent per share against the Zacks Consensus ...

Amicus Therapeutics Stock Sees RS Rating Improve To 74

13d ago, source: Investor's Business Daily on MSN

Amicus Therapeutics stock earns the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Neurocrine Biosciences and Alkermes are among the top 5 highly ...

Amicus’s Growth Trajectory Reinforces Buy Rating Amid Strong Product Prospects and Revenue Milestones

12d ago, source:

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on FOLD stock, giving a Buy rating on February 28. Anupam Rama’s ...

Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)

11d ago, source:

Director Margaret Mcglynn has sold 15,000 shares of Amicus Therapeutics Inc (NASDAQ:FOLD) on March 5, 2024, according to a ...

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

5y ago, source: TheStreet.com

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, ...

FOLD Jul 2024 12.000 call

2d ago, source: Yahoo Finance

Director Margaret Mcglynn has sold 15,000 shares of Amicus Therapeutics Inc (NASDAQ:FOLD) on March 5, 2024, according to a recent SEC Filing.

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

10d ago, source:

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...

Biotech Stock News Bite - Elicio Therapeutics, Inc. (Nasdaq: ELTX) Rises on Funding News

5h ago, source: Investor ideas

Investorideas.com ( Biotech Stock News Bites - Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology ...

The Latest Analyst Ratings For Alignment Healthcare

12d ago, source:

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Alignment Healthcare ...

Veeva Systems Inc Class A

8mon ago, source:

View Veeva Systems Inc Class A VEEV stock quote prices, financial information, real-time forecasts, and company news from CNN.

Review Bombing Case: The Amicus Curiae recommends a 48-hour window for reviews

on MSN ago, source:

The Kerala High Court, with the help of the Amicus Curiae, is considering guidelines to regulate movie reviews by social ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...